ReviewMolecules (Basel, Switzerland)2026
Marine Macroalgal Polysaccharides in Nanomedicine: Blue Biotechnology Contributions in Advanced Therapeutics.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fucoidan-Mediated Biogenic Gold Nanoparticles fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Macroalgal Bloom Biomass as a Source of Bioactive Compounds and Antimicrobial Peptides.Marine drugs · 2026Article
- Fabrication and Functional Modification Strategies of Squid Ink-Derived Nanoparticles: From Natural Melanin to Multifunctional Biomaterials.Marine drugs · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine macroalgae represent a versatile and sustainable platform within blue biotechnology, offering structurally diverse polysaccharides that are making significant contributions to next-generation therapeutical applications. Algae are rich sources of high-value biomolecules, including polysaccharides, vitamins, minerals, proteins, antioxidants, pigments and fibers. Algal biomolecules are widely explored in modern pharmaceuticals due to their range of physiochemical and biological properties. Recently, algal polysaccharides have gained increasing attention in nanomedicine due to their biocompatibility, biodegradability and tunable bioactivity. The nanomedical applications of algal polysaccharides pertain to their anti-coagulant, antiviral, anti-inflammatory, antimicrobial and anti-cancer properties. In this review, we discuss some major macroalgal polysaccharides, such as agar, agarose, funoran, porphyran, carrageenan, alginate and fucoidan, as well as their structure, uses, and applications in nanomedical systems. Both sulfated and non-sulfated polysaccharides demonstrate significant therapeutic properties when engineered into their nanotherapeutic forms. Previous studies show antimicrobial potential of 80-90% antiviral activity > 70%, significant anticoagulant activity, and excellent anticancer responses (up to 80% reductions in cancer cell viability have been reported in nanoformulated versions of polysaccharides). This review discusses structure-function relationships, bioactivities, nanomaterial synthesis and nanomedical applications (e.g., drug delivery, tissue engineering, biosensing, bioimaging, and nanotheranostics). Overall, this review reflects the potential of algal polysaccharides as building blocks in sustainable biomedical engineering in the future healthcare industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.